Rue des Frères Wright 29
About iTeos TherapeuticsiTeos was founded in 2011 as a spin off of the Ludwig Cancer Research (LICR) and de Duve Institute at University of Louvain (UCL). iTeos started its operation in 2012 by building its research insights based upon the unparalleled expertise of the LICR, a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer.
Founder and CEO: Michel Detheux
CSO: Christophe Queva
CMO: Alain Thibault
CFO: Yves Mertens
Please click here for iTeos job opportunities.
Please click here for clinical trial information.
20 articles with iTeos Therapeutics
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that management will participate in two upcoming virtual investor conferences in September.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the second quarter ended June 30, 2020 and recent business highlights.
iTeos Therapeutics, Inc. announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by iTeos.
5/4/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today that it has enrolled the first patient in its Phase 1/2 study with EOS884448 (EOS-448), the company’s investigational ADCC-enabled antagonist anti-TIGIT antibody drug candidate.
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDAⓇ
Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab)
iTeos Therapeutics SA announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the upcoming Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 10:50 a.m.
iTeos Therapeutics SA today announced that management will participate in two upcoming conferences in November.
iTeos Therapeutics SA today announced the presentation of two posters on its novel A2A receptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, taking place from November 7-11, 2018 in Washington, D.C.
iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in September.
With the end of June, numerous biotechs shored up their boards of directors and other advisory boards with new members as the companies continued to shape their future strategies.
Belgium-based iTeos Therapeutics SA completed an oversubscribed Series B financing worth $75 million.
iTeos Therapeutics to Present New Preclinical Data from A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at Molecular Medicine Tri-Conference
iTeos Therapeutics today announces that it will present new data for its A2A antagonist and anti-TIGIT antibody programs.
iTeos Therapeutics today announced that it has regained exclusive worldwide rights from Pfizer to develop and commercialise EOS200271, a highly selective, clinical-stage IDO1 inhibitor.